Skip to content


Explaining the standardized treatment of pancreatic cancer

Work Stream Chair: Sorin Barbu, Professor of Surgery, “Iuliu Hatieganu” University of Medicine & Pharmacy of Cluj-Napoca, Romania

Pancreatic cancer treatment is standardized and should be the same all around the world. Unfortunately, treatment accessibility is highly unequal across European countries. Reimbursement levels, compliance with Guidelines, unequal spread of care facilities and different trainings entail various levels of treatment availability. This work stream aims to present treatment options, communicate on best practices & essential requirements for quality of care and help patients get information on where they can receive specialised care. The work stream will also scrutinise ongoing clinical trials and provide information on current and future treatments, as the possibility to join the randomized controlled trial for physicians & patients.

Reimbursement for anti-cancer drugs vary across European countries. Not all healthcare organisations see the value in reimbursing these drugs for pancreatic cancer patients as their benefit in terms of survival is extremely low1.


Sorin T. Barbu

Sorin T. Barbu is a Professor of Surgery, Chairman of the 4th Surgery Department and member in the Surgery Council at the “Iuliu Hatigeanu” University of Medicine & Pharmacy in Cluj-Napoca, Romania. He has been President of the Romanian Pancreatic Club since 2007, Councillor in the Executive Committee of the European Federation – International Society for Digestive Surgery (EFISDS), member of the UEG Public Affairs Committee and of the European Pancreatic Club since 2002. Before being elected Board Member at the PCE AGM in Barcelona, in June 2018, he has been a member of PCE since 2015.

  1. Lim, Carol Sunghye, et al. “International comparison of the factors influencing reimbursement of targeted anti-cancer drugs.” BMC health services research 14.1 (2014): 595.

Pancreatic Cancer Europe

Related Projects and Activities

The importance of pancreatic cancer’s early detection

Pancreatic cancer is not one of the most frequently diagnosed cancers, but it is one of the most lethal due to its early local extension and metastatic behaviour. Some of the reasons for this high fatality rate are the aggressiveness of the disease, its late diagnosis, especially since symptoms are unspecific and appear rather late, and the available limited therapeutic options.

Nutrition and pancreatic cancer

Malnutrition in cancer patients leads to poorer health outcomes and it results in an increased burden on healthcare resources. In pancreatic cancer (the fourth leading cause of cancer deaths in both genders), more than 80% of patients have a significant weight loss at the time of diagnosis, and develop severe cachexia over time. Therefore, early, aggressive nutritional support is essential. Actual available nutritional therapies, in care centres as well as at home, such as enteral nutrition, parenteral nutrition and special nutritional supplements have a beneficial effect on nutritional status, quality of life and even on patients survival.